Looking at the course of developments — in the healthcare reform "debate" (as it were) and medical technology — it is not a huge leap of judgment to make the following predictions for the ups and downs of healthcare overall and for specific medical technologies.
Predictions for the healthcare market
A healthcare reform package will pass this [...]
A meta-analysis by the Cardiovascular Research Foundation, and published in the June 15 edition of Circulation, of 56 studies that covered 190,000 patients revealed unambiguous benefits for use of drug-eluting stents (DES) instead of bare metal stents.
DES resulted in a reduction in death from no difference (meta-analysis of 22 randomized trials) to a 22% reduction (34 [...]
In spite of arguments contesting whether bare metal or drug-eluting stents perform better, drug-eluting stents are here to stay and are still used in the majority of stent implantations. In fact, a plethora of studies have shown that DES can improve mortality rates and reduce the need for target vessel revascularization (TVR) compared with BMS.
We [...]
This is one of the largest clinical trials comparing PCI (with DES) with CABG. Results presented at TCT 2008 found no significant difference in treatment outcomes of patients who were stented compared with those who underwent coronary artery bypass grafting. Also at TCT 2008, Boston Scientific’s next-generation Liberte stent was shown to have high marks [...]
In addition to bare metal, drug-eluting and absorbable stents on the market or under development for the treatment of coronary artery diseases, innovative companies have developed other types of stents to treat cardiovascular disease. These include bioactive coatings, antibody coatings, biomimetic coatings, hydrophilic coatings, titanium-nitride-oxide coatings, pericardium-covered stents, radioactive stents, synthetic graft alternatives, tissue engineered coatings, stents [...]
Angioplasty for the revascularization of blocked coronary arteries gave way in the evolution of clinical practice to the adjunctive use of bare metal coronary stents, but due to a high frequency of restenosis bare metal stents gave way to drug-eluting stents (DESs) in 2003 (J&J/CYPHER, followed in 2004 by Boston Scientific’s TAXUS, and soon followed by [...]
Cardiovascular disease includes high blood pressure, coronary heart disease (myocardial infarction, angina pectoris), heart failure, stroke, and congenital cardiovascular defects. Roughly 80 million Americans have one or more of these types of heart disease. Of those, more than 38 million are greater than 60 years of age.
Cardiovascular disease is the leading cause of death worldwide [...]
The global market for drug-eluting, bare and bioresorbable stents for the treatment of coronary artery disease is in a "growth and proliferation" phase, as the market for these devices is growing steadily through application to growing patient caseload, and as the number of companies with approved products or products in development multiplies.
The bulk of interest in [...]
Lest anyone believe that drug-eluting coronary stents have taken over the acute myocardial infarction world, a good number of companies are active in the development and marketing of bare metal stents.
See a list of manufacturers below, drawn from the MedMarket Diligence Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017."
Aachen Resonance GmbH
Abbott [...]
There is a wide range of clinical trials evaluating drug-eluting, bare, and resorbable coronary stents for their safety, efficacy and performance. Below are many of the key trials in process or completed.
ABSORB
HORIZONS-AMI
ARRIVE II Registry
ISAR, ISAR-TEST-2
ARTS
LONG DES
AXXESS PLUS
NOBLESS
BASKET
NOBORI
BBC ONE
NORDIC
CARE
OLYMPIA Registry
COREL
PASSION
COSTAR
PREPARE
COURAGE
PROGRESS
CUSTOM
RESOLUTE
DEScover Registry
RESORB
DIRECT
REWARD Registries
DIVERGE
SERIES
e-HEALING
SIMPLE Registries
EASTER Registry
SIRIUS, E-SIRIUS, C-SIRIUS
ENDEAVOR
SORT-OUT III
ETHOS
SPIRIT
EuroSTAR
STEALTH
EVENT Registry
STEMI
FAME
STENT Registry
GENESIS
SVELT
FOCUS
TAXUS
HEALING
TYPHOON
Source: Report #C245, "Worldwide Coronary Stents, 2009-2018."
These trials [...]
Contact:
